Bufexamac

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Bufexamac is a drug used as an anti-inflammatory agent on the skin, as well as rectally. Common brand names include Paraderm and Parfenac. It was withdrawn in Europe because of allergic reactions.

Indications

Ointments and lotions containing bufexamac are used for the treatment of subacute and chronic eczema of the skin, including atopic eczema, as well as sunburn and other minor burns, and itching. Suppositories containing bufexamac in combination with local anaesthetics are used against haemorrhoids.^[1]

Pharmacology

Bufexamac is thought to act by inhibiting the enzyme cyclooxygenase, which would make it a non-steroidal anti-inflammatory drug. Evidence on the mechanism of action is scarce.^[2] Furthermore, bufexamac was identified as a specific inhibitor of class IIB histone deacetylases (HDAC6 and HDAC10),^[3] which may contribute to its clinical efficacy.

Side effects

Bufexamac can cause severe contact dermatitis which is often hard to distinguish from the initial condition.^[4] As a consequence, the European Medicines Agency recommended to withdraw the marketing approval in April 2010.^[5]

References

↑ Dinnendahl, V, Fricke, U, ed. (2010). Arzneistoff-Profile (in German). 2 (23 ed.). Eschborn, Germany: Govi Pharmazeutischer Verlag. ISBN 978-3-7741-9846-3.
↑ Gloor, Max; Thoma, Karl; Fluhr, Joachim (2000). Dermatologische Externatherapie: Unter besonderer Berücksichtigung der Magistralrezeptur (in German). Springer. p. 349. ISBN 3-540-67174-9.
↑ Bantscheff, Marcus; Hopf, Carsten; Savitski, Mikhail M; Dittmann, Antje; Grandi, Paola; Michon, Anne-Marie; Schlegl, Judith; Abraham, Yann; Becher, Isabelle; Bergamini, Giovanna; Boesche, Markus; Delling, Manja; Dümpelfeld, Birgit; Eberhard, Dirk; Huthmacher, Carola; Mathieson, Toby; Poeckel, Daniel; Reader, Valérie; Strunk, Katja; Sweetman, Gavain; Kruse, Ulrich; Neubauer, Gitte; Ramsden, Nigel G; Drewes, Gerard (2011). “Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes”. Nature Biotechnology. 29 (3): 255–65. doi:10.1038/nbt.1759. PMID 21258344.
↑ “Bufexamac: Ein Ekzemtherapeutikum, das selbst häufig allergische Kontaktekzeme hervorruft”. Deutsches Ärzteblatt (in German) (47). 2000.
↑ “European Medicines Agency recommends revocation of marketing authorisations for bufexamac” (PDF). European Medicines Agency. 2010-04-22.

Template:Topical products for joint and muscular pain

[Arzneistoff-Profile-1] Dinnendahl, V, Fricke, U, ed. (2010). Arzneistoff-Profile (in German). 2 (23 ed.). Eschborn, Germany: Govi Pharmazeutischer Verlag. ISBN 978-3-7741-9846-3.

[2] Gloor, Max; Thoma, Karl; Fluhr, Joachim (2000). Dermatologische Externatherapie: Unter besonderer Berücksichtigung der Magistralrezeptur (in German). Springer. p. 349. ISBN 3-540-67174-9.

[3] Bantscheff, Marcus; Hopf, Carsten; Savitski, Mikhail M; Dittmann, Antje; Grandi, Paola; Michon, Anne-Marie; Schlegl, Judith; Abraham, Yann; Becher, Isabelle; Bergamini, Giovanna; Boesche, Markus; Delling, Manja; Dümpelfeld, Birgit; Eberhard, Dirk; Huthmacher, Carola; Mathieson, Toby; Poeckel, Daniel; Reader, Valérie; Strunk, Katja; Sweetman, Gavain; Kruse, Ulrich; Neubauer, Gitte; Ramsden, Nigel G; Drewes, Gerard (2011). “Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes”. Nature Biotechnology. 29 (3): 255–65. doi:10.1038/nbt.1759. PMID 21258344.

[4] “Bufexamac: Ein Ekzemtherapeutikum, das selbst häufig allergische Kontaktekzeme hervorruft”. Deutsches Ärzteblatt (in German) (47). 2000.

[5] “European Medicines Agency recommends revocation of marketing authorisations for bufexamac” (PDF). European Medicines Agency. 2010-04-22.

[1]

[2]

[3]

[4]

[5]